Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/2000

Content (10 Articles)

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?

Rachel S. Rosenberg Zand, Rachel S. Rosenberg Zand, Linda Grass, Angeliki Magklara, Angeliki Magklara, David J.A. Jenkins, Eleftherios P. Diamandis, Eleftherios P. Diamandis

Progression in MCF-7 breast cancer cell tumorigenicity: compared effect of FGF-3 and FGF-4

Amin Hajitou, Christophe Deroanne, Agnès Noël, Julien Collette, Betty Nusgens, Jean-Michel Foidart, Claire-M. Calberg-Bacq

Detection of microsatellite alterations in nipple discharge accompanied by breast cancer

Michihiko Miyazaki, Yasuhiro Tamaki, Isao Sakita, Yoshiyuki Fujiwara, Masao Kadota, Norikazu Masuda, Masaru Ooka, Tadashi Ohnishi, Masayuki Ohue, Mitsugu Sekimoto, Naohiroi Tomita, Junkou Furukawa, Nariaki Matsuura, Morito Monden

Correlation of three-dimensional magnetic resonance imaging with precise histopathological map concerning carcinoma extension in the breast

Goro Amano, Noriaki Ohuchi, Tadashi Ishibashi, Takanori Ishida, Masakazu Amari, Susumu Satomi

Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer

D.W. van Toorn, J.W.R Nortier, M. Rubach, C.A.M. de Swart, J.C. Huldij, H. van Tinteren, J.B. Vermorken, J.B. Vermorken

Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene

Utha Hellmann-Blumberg, Tracy L. Taras, Gregory T. Wurz, Michael W. DeGregorio

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

Zsuzsanna Kahán, Zsuzsanna Kahán, József L. Varga, József L. Varga, Andrew V. Schally, Andrew V. Schally, Zoltán Rékási, Zoltán Rékási, Patricia Armatis, Ioulia Chatzistamou, Ioulia Chatzistamou, Tamás Czömpöly, Tamás Czömpöly, Gábor Halmos, Gábor Halmos

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine